Observational Study of Meloxicam in Mexican Patients With Rheumatic Diseases
- Registration Number
- NCT02184065
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
Observational study to evaluate the efficacy and safety of meloxicam (Mobicox®) in Mexican population with rheumatic diseases
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 22639
Inclusion Criteria
- Age of 12 or older and rheumatologic disease
Exclusion Criteria
- Hypersensitivity to meloxicam
- Hypersensitivity to other Non-steroidal anti-inflammatory drugs (NSAIDS)
- History of asthma, angioedema or urticaria secondary to NSAIDS
- Pregnancy or lactation
- Recent or current history of peptic ulcer disease, severe renal failure and severe hepatic failure
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Meloxicam Meloxicam -
- Primary Outcome Measures
Name Time Method Medical global evaluation on a 4-point scale 30 and 90 days Intensity of symptoms at rest evaluated with a 4-point scale 30 and 90 days Intensity of symptoms during movement evaluated with a 4-point scale 30 and 90 days
- Secondary Outcome Measures
Name Time Method